Comparable stake leader
BlackRock, Inc.
SEC ownership of REPLIGEN CORP
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0000730272.
Disclosed value leader
PRICE T ROWE ASSOCIATES INC /MD/
Comparable rows
50/50
Latest evidence
30 Jun 2026
- Public ticker
- RGEN on Nasdaq
- Parsed ownership sources
-
13D/G and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
BlackRock, Inc.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
BlackRock, Inc.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0000730272
- Issuer location
- Waltham, MA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of REPLIGEN CORP (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
BlackRock, Inc.
Disclosed value leader
PRICE T ROWE ASSOCIATES I...
Comparable rows
50/50
Latest evidence
30 Jun 2026
13D/G
13F
Lead comparable stake: 9.3%
13D/G row: BlackRock, Inc.
Showing 1-8 of 50 holder rows.
Quick read
BlackRock, Inc. leads the comparable SEC ownership view at 9.3%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens BlackRock, Inc.'s linked filing trail.
Comparable ownership
Top 5
BlackRock, Inc.
9.3%
PRICE T ROWE ASSOCIATES INC /MD/
8.2%
FMR LLC
5.1%
VANGUARD CAPITAL MANAGEMENT LLC
5%
Roy T. Eddleman
4.8%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| BlackRock, Inc. |
13D/G
13F
Company
|
9.3%
|
$724,772,059
5,198,107 shares
|
$0 | 31 Mar 2025 |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13D/G
13F
T. Rowe Price Associates, Inc. · Company
|
8.2%
|
$753,733,060
4,599,860 shares
|
+$191,767,488 | 31 Dec 2025 |
| FMR LLC |
13D/G
13F
Company
|
5.1%
|
$473,742,228
2,891,140 shares
|
$0 | 31 Dec 2025 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13D/G
13F
Vanguard Capital Management · Company
|
5%
|
$409,369,886
2,825,579 shares
|
$0 | 30 Jun 2026 |
| Roy T. Eddleman |
13D/G
Roy T. Eddleman Living Trust
|
4.8%
|
$377,254,217
2,705,689 shares
|
$0 | 31 Dec 2024 |
| Roy T. Eddleman Living Trust |
13D/G
|
4.8%
|
$443,354,200
2,705,689 shares
|
$0 | 31 Dec 2025 |
| UNITED CAPITAL FINANCIAL ADVISORS, LLC |
13F
Company
|
4.9%
|
$326,830,324
2,773,980 shares
|
— | 31 Mar 2026 |
| VANGUARD PORTFOLIO MANAGEMENT LLC |
13F
Company
|
4.1%
|
$271,586,175
2,305,094 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$12,615,588.
Buys
$201,830
Insiders: 1
Sells
$12,817,418
Insiders: 5
Net
-$12,615,588
Shares: -86,913
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 1,800
Shares: 88,713
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 1,263 | $0 | $185,785 | -$185,785 |
| 3-6 | 0 | 3,832 | $0 | $536,480 | -$536,480 |
| 6-9 | 0 | 54,507 | $0 | $8,586,764 | -$8,586,764 |
| 9-12 | 1,800 | 29,111 | $201,830 | $3,508,389 | -$3,306,559 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-18 of 18 reporting-owner rows connected to REPLIGEN CORP. Open a relationship link for the CIK-to-CIK filing trail.
Rows
18
Largest Forms 3/4/5 holder
Anthony Hunt
Net 12M change
-$12,615,588
Latest report
16 Jul 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Anthony Hunt | Director | $11,130,078 | -$10,522,607 | -49% | Mixed | 02 Mar 2026 |
| Karen A. Dawes | Director | $10,935,581 | -$44,275 | -0.4% | Mixed | 14 May 2026 |
| Olivier Loeillot | Chief Executive Officer, Director | $7,594,440 | -$1,733,450 | -19% | Filing P/S | 21 Apr 2026 |
| Jon Snodgres | Chief Financial Officer | $5,499,867 | Mixed | 16 May 2023 | ||
| Glenn P. Muir | Director | $4,718,808 | Mixed | 14 May 2026 | ||
| Christine Gebski | SVP, Filtration & Chromatography | $4,478,619 | Mixed | 14 May 2024 | ||
| James Bylund | Chief Operating Officer | $3,488,544 | -$331,301 | -8.7% | Mixed | 05 Mar 2026 |
| Jason K. Garland | Cfo | $2,824,350 | -$185,785 | -6.2% | Filing P/S | 16 Jul 2026 |
| Ralf Kuriyel | Senior VP, R&D | $2,752,907 | Mixed | 05 Mar 2026 | ||
| Martin D. Madaus | Director | $988,745 | +$201,830 | +26% | Mixed | 14 May 2026 |
| Brian Robb Douglass | Chief Product Officer | $940,792 | Mixed | 07 May 2026 | ||
| Manner Carrie Eglinton | Director | $643,415 | Mixed | 14 May 2026 | ||
| Nicolas Barthelemy | Director | $640,469 | Mixed | 14 May 2026 | ||
| Rohin Mhatre | Director | $590,749 | Mixed | 14 May 2026 | ||
| Violetta Hughes | Chief Accounting Officer | $526,655 | Mixed | 02 Sep 2025 | ||
| Konstantin Konstantinov | Director | $458,201 | Mixed | 14 May 2026 | ||
| Margaret Pax | Director | $354,756 | Mixed | 14 May 2026 | ||
| Thomas F. Ryan Jr. | Director | $214,368 | Mixed | 01 Mar 2022 |
Recent insider transactions for REPLIGEN CORP
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Jason K. Garland | RGEN | Common Stock | Sale | -2.74% | $79,500 | $150.00 | -530 | 18,829 | 16 Jul 2026 | Direct |
| Jason K. Garland | RGEN | Common Stock | Sale | -3.65% | $106,285 | $145.00 | -733 | 19,359 | 25 Jun 2026 | Direct |
| Martin D. Madaus | RGEN | Common Stock | Award | 17.8% | 995 | 6,581 | 14 May 2026 | Direct | ||
| Martin D. Madaus | RGEN | Stock Option (Right to Buy) | Award | 2,239 | 2,239 | 14 May 2026 | Direct | |||
| Konstantin Konstantinov | RGEN | Common Stock | Award | 34.4% | 995 | 3,889 | 14 May 2026 | Direct | ||
| Konstantin Konstantinov | RGEN | Stock Option (Right to Buy) | Award | 2,239 | 2,239 | 14 May 2026 | Direct | |||
| Manner Carrie Eglinton | RGEN | Common Stock | Award | 22.3% | 995 | 5,461 | 14 May 2026 | Direct | ||
| Manner Carrie Eglinton | RGEN | Stock Option (Right to Buy) | Award | 2,239 | 2,239 | 14 May 2026 | Direct | |||
| Rohin Mhatre | RGEN | Common Stock | Award | 24.8% | 995 | 5,014 | 14 May 2026 | Direct | ||
| Rohin Mhatre | RGEN | Stock Option (Right to Buy) | Award | 2,239 | 2,239 | 14 May 2026 | Direct | |||
| Margaret Pax | RGEN | Common Stock | Award | 49.4% | 995 | 3,011 | 14 May 2026 | Direct | ||
| Margaret Pax | RGEN | Stock Option (Right to Buy) | Award | 2,239 | 2,239 | 14 May 2026 | Direct | |||
| Glenn P. Muir | RGEN | Common Stock | Award | 2.55% | 995 | 40,051 | 14 May 2026 | Direct | ||
| Glenn P. Muir | RGEN | Stock Option (Right to Buy) | Award | 2,239 | 2,239 | 14 May 2026 | Direct | |||
| Karen A. Dawes | RGEN | Common Stock | Award | 1.08% | 995 | 92,816 | 14 May 2026 | Direct | ||
| Karen A. Dawes | RGEN | Stock Option (Right to Buy) | Award | 2,239 | 2,239 | 14 May 2026 | Direct | |||
| Nicolas Barthelemy | RGEN | Common Stock | Award | 22.4% | 995 | 5,436 | 14 May 2026 | Direct | ||
| Nicolas Barthelemy | RGEN | Stock Option (Right to Buy) | Award | 2,239 | 2,239 | 14 May 2026 | Direct | |||
| Glenn P. Muir | RGEN | Common Stock | Options Exercise | 6.65% | 2,434 | 39,056 | 07 May 2026 | Direct | ||
| Glenn P. Muir | RGEN | Stock Option (Right to Buy) | Options Exercise | 2,434 | 2,434 | 07 May 2026 | Direct | |||
| Brian Robb Douglass | RGEN | Common Stock | Tax liability | -4.01% | -334 | 7,985 | 07 May 2026 | Direct | ||
| Olivier Loeillot | RGEN | Common Stock | Sale | -6.6% | $536,480 | $140.00 | -3,832 | 54,246 | 21 Apr 2026 | Direct |
| Ralf Kuriyel | RGEN | Common Stock | Award | 35.8% | 5,284 | 20,062 | 05 Mar 2026 | Direct | ||
| Ralf Kuriyel | RGEN | Stock Option (Right to Buy) | Award | 5,669 | 5,669 | 05 Mar 2026 | Direct | |||
| Olivier Loeillot | RGEN | Common Stock | Award | 71.1% | 24,134 | 58,078 | 05 Mar 2026 | Direct | ||
| Olivier Loeillot | RGEN | Stock Option (Right to Buy) | Award | 25,890 | 25,890 | 05 Mar 2026 | Direct | |||
| James Bylund | RGEN | Common Stock | Award | 43.9% | 7,751 | 25,423 | 05 Mar 2026 | Direct | ||
| James Bylund | RGEN | Stock Option (Right to Buy) | Award | 8,315 | 8,315 | 05 Mar 2026 | Direct | |||
| Jason K. Garland | RGEN | Common Stock | Award | 62.8% | 7,751 | 20,092 | 05 Mar 2026 | Direct | ||
| Jason K. Garland | RGEN | Stock Option (Right to Buy) | Award | 8,315 | 8,315 | 05 Mar 2026 | Direct | |||
| James Bylund | RGEN | Common Stock | Tax liability | -0.35% | -62 | 17,672 | 04 Mar 2026 | Direct | ||
| James Bylund | RGEN | Common Stock | Award | 0.71% | 125 | 17,734 | 04 Mar 2026 | Direct | ||
| Ralf Kuriyel | RGEN | Common Stock | Tax liability | -0.28% | -42 | 14,778 | 04 Mar 2026 | Direct | ||
| Ralf Kuriyel | RGEN | Common Stock | Award | 0.85% | 125 | 14,820 | 04 Mar 2026 | Direct | ||
| James Bylund | RGEN | Common Stock | Tax liability | -12.1% | -2,433 | 17,609 | 02 Mar 2026 | Direct | ||
| Olivier Loeillot | RGEN | Common Stock | Tax liability | -4.53% | -1,610 | 33,944 | 02 Mar 2026 | Direct | ||
| Anthony Hunt | RGEN | Common Stock | Tax liability | -10% | -9,897 | 89,062 | 02 Mar 2026 | Direct | ||
| Jason K. Garland | RGEN | Common Stock | Tax liability | -5.48% | -715 | 12,341 | 02 Mar 2026 | Direct | ||
| Ralf Kuriyel | RGEN | Common Stock | Tax liability | -5.91% | -923 | 14,695 | 02 Mar 2026 | Direct | ||
| Brian Robb Douglass | RGEN | Common Stock | Tax liability | -2.59% | -221 | 8,319 | 02 Mar 2026 | Direct | ||
| James Bylund | RGEN | Common Stock | Tax liability | -6.87% | -1,478 | 20,042 | 27 Feb 2026 | Direct | ||
| Olivier Loeillot | RGEN | Common Stock | Tax liability | -0.96% | -344 | 35,554 | 27 Feb 2026 | Direct | ||
| Jason K. Garland | RGEN | Common Stock | Tax liability | -2.44% | -327 | 13,056 | 27 Feb 2026 | Direct | ||
| Ralf Kuriyel | RGEN | Common Stock | Tax liability | -2.76% | -444 | 15,618 | 27 Feb 2026 | Direct | ||
| Brian Robb Douglass | RGEN | Common Stock | Award | 36.6% | 2,288 | 8,540 | 31 Dec 2025 | Direct | ||
| Brian Robb Douglass | RGEN | Stock Option (Right to Buy) | Award | 2,143 | 2,143 | 31 Dec 2025 | Direct | |||
| Karen A. Dawes | RGEN | Common Stock | Sale | -0.3% | $44,275 | $161.00 | -275 | 91,821 | 17 Dec 2025 | Direct |
| Glenn P. Muir | RGEN | Common Stock | Options Exercise | 10.1% | 3,366 | 36,622 | 16 Dec 2025 | Direct | ||
| Glenn P. Muir | RGEN | Stock Option (Right to Buy) | Options Exercise | 3,366 | 3,366 | 16 Dec 2025 | Direct | |||
| Anthony Hunt | RGEN | Common Stock | Other | -1.98% | -2,000 | 98,959 | 04 Dec 2025 | Direct |
* marks a reported price that did not pass the local price check.